WO2003051345A3 - Verwendung von verdauungsenzymgemischen zur behandlung pathologischer bakterieller überwucherung des dünndarms von säugetieren und menschen - Google Patents

Verwendung von verdauungsenzymgemischen zur behandlung pathologischer bakterieller überwucherung des dünndarms von säugetieren und menschen Download PDF

Info

Publication number
WO2003051345A3
WO2003051345A3 PCT/EP2002/014148 EP0214148W WO03051345A3 WO 2003051345 A3 WO2003051345 A3 WO 2003051345A3 EP 0214148 W EP0214148 W EP 0214148W WO 03051345 A3 WO03051345 A3 WO 03051345A3
Authority
WO
WIPO (PCT)
Prior art keywords
mammals
humans
small intestine
digestive enzyme
bacterial overgrowth
Prior art date
Application number
PCT/EP2002/014148
Other languages
English (en)
French (fr)
Other versions
WO2003051345A2 (de
Inventor
Robert Tabeling
Christian Mandischer
Daniela Heldt
Josef Kamphues
Peter-Colin Gregory
Original Assignee
Solvay Pharm Gmbh
Robert Tabeling
Christian Mandischer
Daniela Heldt
Josef Kamphues
Peter-Colin Gregory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh, Robert Tabeling, Christian Mandischer, Daniela Heldt, Josef Kamphues, Peter-Colin Gregory filed Critical Solvay Pharm Gmbh
Priority to AU2002364750A priority Critical patent/AU2002364750A1/en
Publication of WO2003051345A2 publication Critical patent/WO2003051345A2/de
Publication of WO2003051345A3 publication Critical patent/WO2003051345A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Es wird die Verwendung von Verdauungsenzymgemischen zur Behandlung pathologischer bakterieller Überwucherung des Dünndarms von Säugetieren und Menschen beschrieben.
PCT/EP2002/014148 2001-12-14 2002-12-12 Verwendung von verdauungsenzymgemischen zur behandlung pathologischer bakterieller überwucherung des dünndarms von säugetieren und menschen WO2003051345A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002364750A AU2002364750A1 (en) 2001-12-14 2002-12-12 Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33943801P 2001-12-14 2001-12-14
US60/339,438 2001-12-14

Publications (2)

Publication Number Publication Date
WO2003051345A2 WO2003051345A2 (de) 2003-06-26
WO2003051345A3 true WO2003051345A3 (de) 2003-07-31

Family

ID=23329006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/014148 WO2003051345A2 (de) 2001-12-14 2002-12-12 Verwendung von verdauungsenzymgemischen zur behandlung pathologischer bakterieller überwucherung des dünndarms von säugetieren und menschen

Country Status (2)

Country Link
AU (1) AU2002364750A1 (de)
WO (1) WO2003051345A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
EP2373791B1 (de) 2009-01-06 2016-03-30 Curelon LLC Zusammensetzungen enhaltend protease, amylase and lipase zur verwendung in der behandlung von staphylococcus aureus-infektionen
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
SE535296C2 (sv) 2010-09-08 2012-06-19 Anara Ab Mognad av mag-tarmkanalen
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
JP6796372B2 (ja) * 2012-01-03 2020-12-09 キュアマーク， リミテッド ライアビリティ カンパニー 神経障害および精神障害の行動症状を治療する方法
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2638088A1 (de) * 1976-08-24 1978-03-02 Degussa Verfahren zur herstellung von verbesserten arzneizubereitungen, die lipase nicht-tierischen ursprungs enthalten
US4447412A (en) * 1983-02-01 1984-05-08 Bilton Gerald L Enzyme-containing digestive aid compostions
DE4332985A1 (de) * 1993-09-28 1995-03-30 Konrad Peter Maria Dr Sommer Arzneimittel zur Behandlung der Dysfunktion des exokrinen Pankreas
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
WO2001043764A2 (en) * 1999-12-17 2001-06-21 Fallon Joan M Methods for treating pervasive development disorders
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
WO2002083926A2 (en) * 2001-04-17 2002-10-24 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2638088A1 (de) * 1976-08-24 1978-03-02 Degussa Verfahren zur herstellung von verbesserten arzneizubereitungen, die lipase nicht-tierischen ursprungs enthalten
US4447412A (en) * 1983-02-01 1984-05-08 Bilton Gerald L Enzyme-containing digestive aid compostions
DE4332985A1 (de) * 1993-09-28 1995-03-30 Konrad Peter Maria Dr Sommer Arzneimittel zur Behandlung der Dysfunktion des exokrinen Pankreas
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
WO2001043764A2 (en) * 1999-12-17 2001-06-21 Fallon Joan M Methods for treating pervasive development disorders
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
WO2002083926A2 (en) * 2001-04-17 2002-10-24 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TABELING R ET AL: "Studies on nutrient digestibilities (pre-caecal and total) in pancreatic duct-ligated pigs and the effects of enzyme substitution.", JOURNAL OF ANIMAL PHYSIOLOGY AND ANIMAL NUTRITION, vol. 82, no. 5, December 1999 (1999-12-01), pages 251 - 263, XP009011940, ISSN: 0931-2439 *

Also Published As

Publication number Publication date
AU2002364750A8 (en) 2003-06-30
WO2003051345A2 (de) 2003-06-26
AU2002364750A1 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
WO2003051345A3 (de) Verwendung von verdauungsenzymgemischen zur behandlung pathologischer bakterieller überwucherung des dünndarms von säugetieren und menschen
EP1429617A4 (de) Verfahren zur sterilisierung von verdauungsenzympräparaten
WO2003024392A3 (en) Compositions and methods for the diagnosis and treatment of tumor
MXPA03005960A (es) Nuevas mezclas de enzimas microbianas.
WO2003000113A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003033720A8 (en) Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
AU2003299961A1 (en) Capsule and method for treating or diagnosing conditions or diseases of the intestinal tract
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
WO2003088897A3 (en) Fab i inhibitors
TR199600516A2 (tr) Kakaonun enzimatik muamelesi.
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
ZA200007641B (en) Treatment of airborne allergens.
AU2002225219A1 (en) Diagnosis and treatment of multiple sclerosis
ZA200007642B (en) Treatment of airborne microorganisms.
WO2003099217A3 (en) Methods of treating bacterial infections and diseases associated therewith
WO2006110760A3 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003290605A1 (en) Compositions and methods for the diagnosis and treatment of sepsis
AU2002356868A1 (en) Methods for the prevention or treatment of bacterial and fungal infections
WO2000021513A3 (en) Methods for treating multiple sclerosis
AU2002217316A1 (en) Use of terpenes for the treatment of digestive tract infections
AU2003230952A1 (en) Treatment of mucositis
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
AU2002306600A1 (en) Sperm protein 17 for the diagnosis and treatment of cancer
AU2002334761A1 (en) Methods of treating drug-resistant bacterial infections
WO2004020466A8 (en) Protein tyrosine phosphatase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP